Skip to main content

Endo International Plc., Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP’s bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter.

Five drugmakers battling the cases – Endo, J&J, Teva Pharmaceutical Industries Ltd, Allergan Plc and Mallinckrodt Plc – are looking to enact a global settlement of the litigation that would be implemented through Purdue’s Chapter 11 case, the WSJ reported citing a person familiar with the matter.

The mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability, according to the report.

OxyContin maker Purdue filed for bankruptcy protection in September, succumbing to pressure from more than 2,600 lawsuits alleging the company helped fuel the deadly U.S. opioid epidemic.

Purdue, Mallinckrodt, Endo, J&J, Teva and Allergan were not immediately available to Reuters’ requests for comment.

Report an editorial error

Report a technical issue

Tickers mentioned in this story

Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 28/05/24 8:18am EDT.

SymbolName% changeLast
JNJ-N
Johnson & Johnson
+0.02%147
TEVA-N
Teva Pharmaceutical Industries ADR
+0.48%16.68

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe